Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

Oct 29, 2020
|
staff reporter

NEW YORK – Mammoth Biosciences said on Thursday that it has signed agreements with MilliporeSigma and Hamilton Company to commercialize a high-throughput, CRISPR-based SARS CoV-2 test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Mouse Vision Restored

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

Kids' Vaccine Trial Planned

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

Side Effect Suit in India

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

Nature Papers Present Tool for Targeted Nanopore Sequencing, Crop Genetic Diversity, More

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.

What's Popular?

In Business News

  1. Twist Bioscience Proposes $250M Public Offering

  2. Judge Denies Natera Motion to Invalidate CareDx, Stanford Patents

  3. Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

  4. NanoString Technologies Reveals New High-Resolution Spatial Omics Platform Due 2022

    Premium

  5. Thermo Fisher Scientific Raises Q4 and 2020 Revenue, Earnings Guidance

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.